Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE.
AMIKIN vs NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane integrity, and interfere with cell wall synthesis, respectively. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Apply to affected area 3-4 times daily. Not for use in eyes.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Neomycin: 2-3h (normal renal); polymyxin B: 4-6h (normal renal), prolonged to 2-3 days in renal impairment; bacitracin: ~1.5h after IM; hydrocortisone: 1.5-2h (plasma). Topical: systemic levels negligible.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Neomycin: >90% renal (unchanged) after parenteral; polymyxin B: ~60% renal (unchanged) over 72h; bacitracin: >90% renal (unchanged) after IM; hydrocortisone: hepatic metabolism, metabolites renally eliminated (<1% unchanged). Topical: negligible systemic absorption across intact skin (except bacitracin may be minimally absorbed).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic